London Daily

Focus on the big picture.
Friday, Oct 24, 2025

Hong Kong Covid-19 panel backs Pfizer vaccine, seeks more Norway deaths details

Hong Kong Covid-19 panel backs Pfizer vaccine, seeks more Norway deaths details

Unanimous backing from experts will go before health secretary for final decision, paving way for mass inoculation drive from mid-February.

A government advisory panel has recommended the approval of the Pfizer-BioNTech Covid-19 vaccine for emergency use in Hong Kong, although it said a “circuit-breaking” mechanism could stop a mass inoculation campaign from being rolled out amid heightened concerns over serious side effects from the jab.

The panel of experts meeting on Monday took three hours to give their unanimous backing to the vaccine developed by the American pharmaceutical giant Pfizer and German company BioNTech, paving the way for the jabs scheme after Lunar New Year. The recommendation will now go before the health secretary for a final decision.

The 12-member Advisory Panel on Covid-19 Vaccines pored over thousands of pages of trial data and other material to offer their verdict on the efficacy and safety of the jab.

Its convenor, Professor Wallace Lau Chak-sing, said the panel decided to recommend use of the vaccine after concluding the benefits outweighed the risks, considering all the information provided.

“After discussing it thoroughly at the meeting, all 12 members of the panel have decided to recommend the approval of the use of the vaccine,” Lau told a press conference.

Phase three trials showed the vaccine achieved an efficacy rate of about 95 per cent for recipients over the age of 16, but recent reports of serious side effects had raised concerns.

Lau said the panel would seek more information from Fosun Pharmaceutical – the mainland China partner of BioNTech – and regulatory agencies in Norway, where at least 29 elderly recipients of the jab died.

“According to the information we have got, in Norway, up to 42,000 have actually received the vaccine,” Lau said, adding that of the 29 deaths, “13 have been suggested to be probably related to the vaccine”.

He said the panel still needed more data from Fosun on the causes of death of the 13.

“We understand they were all elderly, they all had multiple different medical conditions,” he said.

“We need to know whether their deaths were actually related to their underlying problems or to the vaccine.”

Citing Pfizer-BioNTech’s data, Lau said on average only 11.1 people per 1 million had a serious allergic reaction. He said more data would also be sought from Germany, where 10 people had died out of 800,000 recipients.

Addressing reports of recipients developing Bell’s palsy, a temporary facial paralysis, Lam said the condition could be treated with steroids.

Panel member Professor David Hui Shu-cheong added the condition usually affected one in every 100,000 people and just one country had reported a higher than normal rate post-inoculation.

Asked why the panel did not wait for extra data on mortality rates overseas, Lau said only that the experts would continue to look into side effects elsewhere.

Lau also did not detail the circumstances under which the panel would recommend the government halt use of the vaccines.

“I think it will be very difficult to say here what are the clear definitions [when we will recommend the Food and Health Bureau stop use of the vaccine],” he said.

“It really depends on the overall benefits of this vaccine to the population of Hong Kong and the possible side effects that we will encounter later on.”

The panel is made up of public health, infectious disease, immunology, drug regulation and clinical care experts.

Lau is a former president of the Hong Kong Academy of Medicine and chair of rheumatology and clinical immunology at the University of Hong Kong.


Hong Kong has also procured Beijing-based Sinovac’s vaccine.


Two infectious disease experts, Dr Leung Chi-chiu and Dr Joseph Tsang Kay-yan, who are not on the panel, agreed with the decision, saying it was needed to get the roll-out moving, as the remaining approval procedures could still take time.

Leung believed that if the panel had failed to reach a decision, Pfizer-BioNTech could have delayed the delivery of the vaccine, as the companies had already held up supplies to some European countries.

He added recent reports did not show significant side effects of the vaccine in younger recipients, so the government could still tweak the inoculation order and protect vulnerable elderly residents if necessary.

A government spokesman welcomed the panel’s recommendation, and said the secretary for food and health would reach her decision as soon as possible.

The Post reported last week that the Pfizer-BioNTech vaccine was the first to apply for an emergency roll-out in Hong Kong, submitting its application in early January.

Hong Kong has reached purchase agreements for three vaccines, procuring 7.5 million doses of each. Aside from the Pfizer-BioNTech jabs, supplied by Fosun Pharma, the city has also procured Beijing-based Sinovac’s vaccine and one jointly developed by British-Swedish pharmaceutical firm AstraZeneca and Oxford University.

The city aims to roll out the inoculation programme after the Lunar New Year holiday in mid-February, with priority given to high-risk groups such as the elderly and health care workers.

Originally, Sinovac’s doses were expected to arrive in the city this month, followed by Pfizer-BioNTech shots in the first quarter and the AstraZeneca vaccine in the middle of the year.

Newsletter

Related Articles

0:00
0:00
Close
Microsoft AI CEO: ‘We’re making an AI that you can trust your kids to use’ — but can Microsoft rebuild its own trust before fixing the industry’s?
China and Russia Deploy Seductive Espionage Networks to Infiltrate U.S. Tech Sector
Apple’s ‘iPhone Air’ Collapses After One Month — Another Major Misstep for the Tech Giant
Graham Potter Begins New Chapter as Sweden Head Coach on Short-Term Deal
Ecuadorian President Daniel Noboa Alleges Poison Plot via Chocolate and Jam
Lakestar to Halt External Fundraising as Investor in Revolut and Spotify
U.S. Innovation Ranking Under Scrutiny as China Leads Output Outputs but Ranks 10th
Three Men Arrested in London on Suspicion of Spying for Russia
Porsche Reverses EV Strategy as New CEO Bets on Petrol and Hybrids
Singapore’s Prime Minister Warns of ‘Messy’ Transition to Post-American Global Order
Andreessen Horowitz Sets Sights on Ten-Billion-Dollar Fund for Tech Surge
US Administration Under President Donald Trump Reportedly Lifts Ban on Ukraine’s Use of Storm Shadow Missiles Against Russia
‘Frightening’ First Night in Prison for Sarkozy: Inmates Riot and Shout ‘Little Nicolas’
White House Announces No Imminent Summit Between Trump and Putin
US and Qatar Warn EU of Trade and Energy Risks from Tough Climate Regulation
Apple Challenges EU Digital Markets Act Crackdown in Landmark Court Battle
Nicolas Sarkozy begins five-year prison term at La Santé in Paris
Japan stocks surge to record as Sanae Takaichi becomes Prime Minister
This Is How the 'Heist of the Century' Was Carried Out at the Louvre in Seven Minutes: France Humiliated as Crown with 2,000 Diamonds Vanishes
China Warns UK of ‘Consequences’ After Delay to London Embassy Approval
France’s Wealthy Shift Billions to Luxembourg and Switzerland Amid Tax and Political Turmoil
"Sniper Position": Observation Post Targeting 'Air Force One' Found Before Trump’s Arrival in Florida
Shouting Match at the White House: 'Trump Cursed, Threw Maps, and Told Zelensky – "Putin Will Destroy You"'
Windows’ Own ‘Siri’ Has Arrived: You Can Now Talk to Your Computer
Thailand and Singapore Investigate Cambodian-Based Prince Group as U.S. and U.K. Sanctions Unfold
‘No Kings’ Protests Inflate Numbers — But History Shows Nations Collapse Without Strong Executive Power
Chinese Tech Giants Halt Stablecoin Launches After Beijing’s Regulatory Intervention
Manhattan Jury Holds BNP Paribas Liable for Enabling Sudanese Government Abuses
Trump Orders Immediate Release of Former Congressman George Santos After Commuting Prison Sentence
S&P Downgrades France’s Credit Rating, Citing Soaring Debt and Political Instability
Ofcom Rules BBC’s Gaza Documentary ‘Materially Misleading’ Over Narrator’s Hamas Ties
Diane Keaton’s Cause of Death Revealed as Pneumonia, Family Confirms
Former Lostprophets Frontman Ian Watkins Stabbed to Death in British Prison
"The Tsunami Is Coming, and It’s Massive": The World’s Richest Man Unveils a New AI Vision
Outsider, Heroine, Trailblazer: Diane Keaton Was Always a Little Strange — and Forever One of a Kind
Dramatic Development in the Death of 'Mango' Founder: Billionaire's Son Suspected of Murder
Two Years of Darkness: The Harrowing Testimonies of Israeli Hostages Emerging From Gaza Captivity
EU Moves to Use Frozen Russian Assets to Buy U.S. Weapons for Ukraine
Europe Emerges as the Biggest Casualty in U.S.-China Rare Earth Rivalry
HSBC Confronts Strategic Crossroads as NAB Seeks Only Retail Arm in Australia Exit
U.S. Chamber Sues Trump Over $100,000 H-1B Visa Fee
Shenzhen Expo Spotlights China’s Quantum Step in Semiconductor Self-Reliance
China Accelerates to the Forefront in Global Nuclear Fusion Race
Yachts, Private Jets, and a Picasso Painting: Exposed as 'One of the Largest Frauds in History'
Australia’s Wedgetail Spies Aid NATO Response as Russian MiGs Breach Estonian Airspace
McGowan Urges Chalmers to Cut Spending Over Tax Hike to Close $20 Billion Budget Gap
Victoria Orders Review of Transgender Prison Placement Amid Safety Concerns for Female Inmates
U.S. Treasury Mobilises New $20 Billion Debt Facility to Stabilise Argentina
French Business Leaders Decry Budget as Macron’s Pro-Enterprise Promise Undermined
Trump Claims Modi Pledged India Would End Russian Oil Imports Amid U.S. Tariff Pressure
×